1. Home
  2. FURY vs KLRS Comparison

FURY vs KLRS Comparison

Compare FURY & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fury Gold Mines Limited

FURY

Fury Gold Mines Limited

HOLD

Current Price

$0.57

Market Cap

115.8M

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$3.30

Market Cap

92.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FURY
KLRS
Founded
2008
2019
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.8M
92.8M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
FURY
KLRS
Price
$0.57
$3.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$1.70
$19.00
AVG Volume (30 Days)
320.9K
49.1K
Earning Date
08-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
75.70
EPS
N/A
N/A
Revenue
N/A
$165,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$3.03
52 Week High
$1.02
$11.88

Technical Indicators

Market Signals
Indicator
FURY
KLRS
Relative Strength Index (RSI) 41.70 33.45
Support Level $0.51 $3.03
Resistance Level $0.57 $4.37
Average True Range (ATR) 0.03 0.21
MACD -0.01 -0.07
Stochastic Oscillator 1.98 12.50

Price Performance

Historical Comparison
FURY
KLRS

About FURY Fury Gold Mines Limited

Fury Gold Mines Ltd is a Canadian-focused high-grade gold exploration company. The company's projects are strategically positioned in two prolific mining regions: the Eeyou Istchee James Bay Region of Quebec and the Kitikmeot Region in Nunavut. Fury Gold's project portfolio comprises the Committee Bay gold project in Nunavut, and the Eau Claire gold, Sakami gold, Elmer East gold and lithium, and Eleonore South gold projects in Quebec. Additionally, it also owns interests in the Kipawa rare earths project and has full ownership of the Zeus heavy rare earths project, both located in the Temiscamingue region of Quebec. The company operates in two reportable segments: Quebec and Nunavut.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: